Keep Informed on Legal and Compliance Developments Affecting Diagnostic Labs
Best practices and expert insight to help lab professionals comply with regulations and identify strategic trends in business and technology
Already a Subscriber? Log in Here
Lab Industry Advisor Subscription
Keeps you up to date on the latest legal, compliance, and business developments affecting the lab industry, while offering analysis and insight to ensure your lab’s success.
![Essential](https://www.g2intelligence.com/wp-content/uploads/2023/11/Essential.png)
![62934_G2_Subscription Website Images_JL V1](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V1.png)
![Special-Report](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Report.png)
![62934_G2_Subscription Website Images_JL V12](https://www.g2intelligence.com/wp-content/uploads/2023/11/62934_G2_Subscription-Website-Images_JL-V12.png)
![Special-Analysis](https://www.g2intelligence.com/wp-content/uploads/2023/11/Special-Analysis.png)
![Elite](https://www.g2intelligence.com/wp-content/uploads/2023/11/Elite.png)
Additional Business Intelligence Offerings
Lab Industry Advisor Subscriptions Include
![paper_magnifing_glass_512](https://www.g2intelligence.com/wp-content/uploads/2023/11/paper_magnifing_glass_512.png)
Analysis and insight on key compliance, legal, and business developments affecting laboratories
- Updates on changes to regulations
- Healthcare-related laws
- FDA approvals
- Business deals in the diagnostics space, and more
Latest Articles
New FDA LDTs Guidance Offers Useful Summary, But Questions Remain
Recently released document for small labs offers a more digestible version of the final rule requirements but still lacks key details
ML Model Predicts Cancer Patient Response to Immunotherapy
New tool helps determine whether immunotherapy is a better option for patients than chemotherapy or radiotherapy.
GAO: FDA Needs Policy to Avoid Repeating EUA COVID-19 Test Mistakes
In a recent report, the GAO says the agency needs a policy when it comes to enforcement discretion regarding tests approved via EUA.
AI and Wearable Devices Offer Promise as an Early COVID-19 ID Method
While still in its infancy, recent research shows the combination of AI and wearables can accurately detect early SARS-CoV-2 infection.
Diagnostic Lab to Pay Nearly $10 Million to Settle FCA Allegations
BioReference Health LLC and its parent company have agreed to pay $9.85 million to resolve alleged violations of the False Claims Act.
NCCN Recommends Molecular Testing for Pediatric Cancer Treatment
The new guidelines will likely prove highly influential with oncologists and payors.
CDC, Major Laboratory Companies Launch New Tests for Monkeypox
As the outbreak continues to grow in countries that have not historically seen monkeypox cases, testing companies are stepping up.
Lesion Samples Are Best When It Comes to Monkeypox Testing
Recent FDA Safety Communication warns of the potential of false results from other sample types when testing for the monkeypox virus.
GAO to FDA: Create Emergency Powers Policy to Avoid COVID Mistakes
The agency needs a plan on use of EUA authority to get lab tests to market during the next public health emergency, says the GAO.
OIG Calls Out MA Plans for Wrongfully Denying Reimbursement
The new report could be a turning point in the battle to curb payor abuse of preauthorization requirements.
Labs Figure Prominently in New OIG Enforcement Report
While the report’s most significant findings involved labs and lab testing, it wasn’t just the usual finger pointing this time.